Dr Reddys Labs launches Hyalosyn
By Nisha Das | 06 Nov 2001
Mumbai: The Hyderabad-based Dr Reddys Laboratories (DRL) has launched Hyalosyn (sodium hyaluronate), an intra-articular injection that provides relief from knee-joint stiffness and immobility among patients suffering from severe osteoarthritis. Hyalosyn is being launched under a co-marketing arrangement with Gland Pharma, a pharmaceutical company in Hyderabad well known for the production of pre-filled injectables.
A DRL press release
issued here said the introduction of Hyalosyn would further
strengthen the companys arthritis franchise in which it is
already a leading player in the domestic market. Hyalosyn is an
emerging therapy for osteoarthritis known as Viscosupplementation.
Hyaluronic acid, the active substance in Hyalosyn, a naturally
occurring substance found in Synovial fluid, which surrounds the
joints. Hyaluronic acid acts as a lubricant that enables bones to
move smoothly over each other and also acts as a shock absorber
for joints.
Osteoarthritis
is a widely prevalent disease. More than 90 per cent of people
above the age of 45 are estimated to show signs of this disease,
and it is the leading cause of disability in people above the age
of 65. Hyalosyn will be marketed as a sterile, pre-filled syringe
containing 20 mg/2ml of sodium hyaluronate. Hyalosyn will provide
the much-needed relief to patients suffering from severe
osteoarthritis and will enable them to resume their daily
activities, the release said.
.webp)
